Navigation Links
Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
Date:10/2/2007

Company enters $800 million market; Initial focus on oncology: most actively researched disease area Researchers to benefit from improved

reagent performance and enhanced productivity

NEWARK, Del., Oct. 2 /PRNewswire-FirstCall/ -- Strategic Diagnostics Inc. (Nasdaq: SDIX) -- today announced the launch of a new internet based catalog of antibody reagents in support of oncology-based research and discovery. These high-quality reagents have all been manufactured utilizing SDI's proprietary Genomic Antibody Technology(TM) and will carry the SEQer(TM) brand. The catalog is available at http://antibodies.sdix.com online.

The catalog has launched with an initial offering of over 200 affinity purified antibody reagents. The Company will supplement this with up to an additional 25 new reagents each week as it strives to become recognized as the fastest-growing site of high quality, leading edge reagents for cancer research.

"Standard antibody production technologies have not changed in more than 20 years," commented Matthew H. Knight, the Company's President and Chief Executive Officer. "The SEQer antibodies in this catalog represent a breakthrough in antibody production and deliver multiple high performance attributes that reduced time, effort and data variation in the laboratory. In addition, the process that produces these reagents is high throughput as evidenced by our initial commitment to add up to 25 new antibody reagents each week. As recognition of SEQer antibody performance grows, we intend to increase this rate."

Mr. Knight continued, "The launch of the SEQer catalog is a direct response to market research highlightin
'/>"/>

SOURCE Strategic Diagnostics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Answerthink and LORENZ Life Sciences Group Announce Strategic Alliance for the SAP Life Science Industry
2. New Advances in Gastric Diagnostics: Smaller is Better
3. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
4. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
7. Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy
8. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
9. Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal Antibody IMC-A12 Presented at ASCO
10. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
11. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015 The Temple Health & Bioscience District ... 5,000-square-foot building at 1802 South First St. in the Temple ... the City of Temple to receive ... the Central Texas Veterans Health Care System, the new facility ... early stage biotechnology and life science companies. ...
(Date:3/27/2015)... March 27, 2015 A new report from Kalorama ... – Chile , ... top targets for IVD firms.  The healthcare research firm said ... IVD strategies for the Latin American continent with a population ... distributed supply operations. However, the country,s regional economic clout does ...
(Date:3/27/2015)... LAS VEGAS , March 27, 2015 Zimmer ... more efficient external fixation system for trauma patients. ... the XtraFix ® External Fixation System from ... design technology and materials.   The XtraFix ... and clamps from the external fixation process, resulting in saved ...
Breaking Medicine Technology:Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 4Zimmer Debuts New Modular External Fixation System 2Zimmer Debuts New Modular External Fixation System 3
... Transdermal System CIII 20 mcg/hour provided significantly ... compared to Butrans 5 mcg/hour when used in opioid-experienced ... according to a pivotal Phase 3 clinical study published ... of Pain . (Logo: http://photos.prnewswire.com/prnh/20100921/NY67262) ...
... SILVER SPRING, Md., Sept. 23, 2011 The U.S. ... treat patients with atypical Hemolytic Uremic Syndrome (aHUS), a ... kidney (renal) failure and is also associated with increased ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Atypical HUS accounts ...
Cached Medicine Technology:Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 2Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 3Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 4Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 5Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 6FDA Approves Soliris for Rare Pediatric Blood Disorder 2FDA Approves Soliris for Rare Pediatric Blood Disorder 3
(Date:3/29/2015)... 2015 The Contract Research Organizations ... research, manage data results and help develop and ... regulation standards. Contract research organizations (CROs) mainly serve ... sectors. Industry operators provide clients with a full ... research for Food and Drug Administration (FDA) approval. ...
(Date:3/29/2015)... (PRWEB) March 29, 2015 North American ... PT Online Continuing Education Courses . ... hours of CME - TPTA, approval # 56399TX      ... evaluation of the shoulder complex - 10.5 hours - ... #56400TX , Examination and Treatment of the SI Joint ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 "Necrorun" was ... which takes a look at the latest and coolest ... Joe Troohey, the host of NewsWatch and technology expert, ... this is an entertaining endless runner game with knights, ... game was released in 2009, according to Eurogamer. The ...
(Date:3/28/2015)... Emergency Medical Care (EMC), a New ... recently commemorated its three-year anniversary of being the only ... to 24-hour urgent care, Emergency Medical Care offers its ... time, Emergency Medical Care’s Urgent Care NYC ... eye injuries, ear infections, fevers, insect bites, burns, animal ...
(Date:3/28/2015)... 28, 2015 One in three young ... research presented today at the American Orthopaedic Society for ... examined the long term success of surgery for patients ... survey data from 242 patients who underwent ACL reconstruction ... Roe, MBBS, FRACS, from North Sydney Orthopaedic and Sports ...
Breaking Medicine News(10 mins):Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 4Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2
... Jan. 3 Continuing its role as ... organizations, the,American Association of Preferred Provider Organizations ... Care Administrators Association,(HCAA) that will significantly enhance ... consolidation and increased consumerism continue to fuel,further ...
... and Hispanic ethnic groups and others with a family history of ... glaucoma are particularly vulnerable, ... have no early symptoms and do not notice as their peripheral,vision ... the,three million Americans with the disease are unaware of their condition.,January ...
... In an era of expanding competition,from generics, expiring ... in new drug discoveries, there is very little ... report by Kalorama Information entitled Drug,Pricing and Reimbursement ... companies the information they need to,reevaluate their pricing ...
... 3 RxElite, Inc. (OTC,Bulletin Board: RXEI), a ... products, announced today that a registration,statement covering the ... effective by the Securities and Exchange Commission on ... informational purposes only, and does not,represent a solicitation ...
... finds one-hour session produces as much carbon monoxide as a ... A leisurely hour of puffs from a hookah -- a ... -- packs the same carbon monoxide punch as a pack-a-day ... looks at a single toxic gas, making it impossible to ...
... Emory University have developed a novel anti-tumor compound that represents ... points" for cancer cells. , The results of research on ... of Cancer Research. The article is highlighted on the cover. ... human patients with solid tumors in 2007. , The idea ...
Cached Medicine News:Health News:AAPPO and HCAA Form Partnership to Enhance Services to Meet the Changing Business Needs of PPOs and TPAs 2Health News:Knowing Your Risks Can Stop the Sneak Thief of Sight 2Health News:Knowing Your Risks Can Stop the Sneak Thief of Sight 3Health News:Generic Onslaught Makes Drug Pricing Decisions More Critical Than Ever 2Health News:RxElite Registration Statement Declared Effective by Securities and Exchange Commission 2Health News:Hookah Smoking as Tough on Lungs as Cigarettes 2Health News:Hookah Smoking as Tough on Lungs as Cigarettes 3Health News:Novel anticancer strategy moves from laboratory to clinic 2Health News:Novel anticancer strategy moves from laboratory to clinic 3
... EVLT, the #1 physician choice in ... advantages to remedying superficial vein reflux. EVLT ... to surgical vein stripping that effectively and ... laser fiber to occlude the vein. The ...
... Aculens 186 UV combines the latest technology ... measurement of ultra violet transmission and auto ... is also programmed to network with the ... Instruments, today, or in the future. , ...
Inquire...
...
Medicine Products: